Survodutide vs Tirzepatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Survodutide

Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.

Full details →

Tirzepatide

Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.

Full details →

Side-by-Side Comparison

Aspect	Survodutide	Tirzepatide
Mechanism	Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes.	Tirzepatide is based on the GIP peptide sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. GIP receptor activation enhances the effects of GLP-1 signaling: (1) potentiated insulin secretion beyond GLP-1 alone, (2) improved beta-cell function, (3) enhanced adipose tissue signaling that may improve fat metabolism, (4) potential protection against GLP-1-induced nausea via GIP receptor activity. The peptide has a C20 fatty diacid moiety enabling albumin binding and once-weekly dosing (half-life ~5 days). The dual mechanism explains the superior weight loss and glycemic outcomes compared to selective GLP-1 agonists.
Typical Dosage	Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing.	For weight management (Zepbound): start at 2.5 mg weekly for 4 weeks. Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg. May increase to 12.5 mg, then maximum 15 mg weekly. For type 2 diabetes (Mounjaro): same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response.
Administration	Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027.	Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior.
Side Effects	Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists.	Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation.
Best For	Weight Loss Liver Health	Weight Loss Diabetes Management